StockData
Transcode Therapeutics, Inc. logo

Transcode Therapeutics, Inc. (RNAZ) stock

RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.41+0.06 (+4.44%)

Close on Nov 17, 2026Market cap $1.43MP/E –Yield –

Transcode Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

No price to sales ratio figures for Transcode Therapeutics

Transcode Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Transcode Therapeutics figures

See a number that looks wrong?